Polymorphisms in intron 1 of the EGFR gene in non‑small cell lung cancer patients

Shitara,Masayuki; Sasaki,Hidefumi; Yokota,Keisuke; Okuda,Katsuhiro; Hikosaka,Yu; Moriyama,Satoru; Yano,Motoki; Kawaguchi,Tomoya; Kubo,Akihito; Takada,Minoru; Kitahara,Naoto; Okumura,Meinoshin; Matsumura,Akihide; Iuchi,Keiji; Fujii,Yoshitaka

doi:10.3892/etm.2012.681

Polymorphisms in intron 1 of the EGFR gene in non‑small cell lung cancer patients

Authors:
- Masayuki Shitara
- Hidefumi Sasaki
- Keisuke Yokota
- Katsuhiro Okuda
- Yu Hikosaka
- Satoru Moriyama
- Motoki Yano
- Tomoya Kawaguchi
- Akihito Kubo
- Minoru Takada
- Naoto Kitahara
- Meinoshin Okumura
- Akihide Matsumura
- Keiji Iuchi
- Yoshitaka Fujii
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan, Department of Internal Medicine, National Hospital Organization, Kinki-chuo Chest Medical Center, Sakai, Osaka 591-8555, Japan, Department of Surgery, National Hospital Organization, Kinki-chuo Chest Medical Center, Sakai, Osaka 591-8555, Japan
Published online on: August 23, 2012 https://doi.org/10.3892/etm.2012.681
Pages: 785-789

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The epidermal growth factor receptor (EGFR) gene is highly polymorphic and its expression and activity may be affected by various polymorphisms. There have been several studies examining associations between EGFR polymorphisms and clinical outcome of lung cancer therapy; however, the underlying mechanism is largely unknown. The present study investigated EGFR polymorphism status and its correlation with clinicopathological features in Japanese non-small cell lung cancer (NSCLC) patients. We investigated 5 polymorphisms in the EGFR gene (-216G/T, -191C/A, 8227G/A, D994D and R497K) in 274 surgically-treated NSCLC patients. TaqMan single nucleotide polymorphism (SNP) genotyping assays and a PCR-based assay were used to analyze these polymorphisms. In our cohort of patients we did not find any evidence of the -191C/A polymorphism. Our results showed that the patients with the 8227GA or AA type in intron 1 had a significantly better prognosis with the anti-EGFR therapy than the patients with the GG type (p=0.0448) in terms of recurrence of lung cancer. No significant association was observed between 3 other SNPs (-216G/T, D994D and R497K) and clinicopathological features. The EGFR 8227G/A polymorphism in intron 1 may be associated with clinical outcome in NSCLC patients treated with EGFR tyrosine kinase inhibitors.

View Figures

View References

1	Ginsberg RJ, Kris K and Armstrong G: Cancer of the lung. Principles and Practice of Oncology. DeVita VT, Hellman S and Rosenberg SA: 4th edition. JB Lippincott Co; Philadelphia, PA: pp. 673–682. 1993
2	Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer. 37:S9–S15. 2001. View Article : Google Scholar
3	Onn A, Choe DH, Herbst RS, et al: Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res. 10:136–143. 2004. View Article : Google Scholar : PubMed/NCBI
4	Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
5	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
6	Fukuoka M, Wu Y-L, Thongprasert S, et al: Biomarker analyses and first overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar
7	Liu W, Innocenti F, Wu MH, et al: A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 65:46–53. 2005.PubMed/NCBI
8	Liu W, Wu X, Zhang W, et al: Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res. 13:6788–6795. 2007. View Article : Google Scholar
9	Brandt B, Meyer-Staeckling S, Schmidt H, et al: Mechanisms of EGFR gene transcription modulation: relationship to cancer risk and therapy response. Clin Cancer Res. 12:7252–7260. 2006. View Article : Google Scholar : PubMed/NCBI
10	Liu W, Innocenti F, Chen P, et al: Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res. 9:1009–1012. 2003.PubMed/NCBI
11	Ma F, Sun T, Shi Y, et al: Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer. 66:114–119. 2009. View Article : Google Scholar : PubMed/NCBI
12	Liu G, Gurubhagavatula S, Zhou W, et al: Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J. 8:129–138. 2008. View Article : Google Scholar : PubMed/NCBI
13	Tiseo M, Capelletti M, De Palma G, et al: Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. J Thorac Oncol. 3:1104–1111. 2008. View Article : Google Scholar : PubMed/NCBI
14	Jou YS, Lo YL, Hsiao CF, et al: Association of an EGFR intron 1 SNP with never smoking female lung adenocarcinoma patients. Lung Cancer. 64:251–256. 2009. View Article : Google Scholar : PubMed/NCBI
15	Endo K, Konishi A, Sasaki H, et al: Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer. 50:375–384. 2005. View Article : Google Scholar : PubMed/NCBI
16	De la Vega FM, Lazaruk KD, Rhodes MD and Wenz MH: Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP Genotyping Assays and the SNPlex Genotyping System. Mutat Res. 573:111–135. 2005.PubMed/NCBI
17	Sasaki H, Okuda K, Shimizu S, et al: EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer. J Cancer Res Clin Oncol. 135:313–318. 2009. View Article : Google Scholar : PubMed/NCBI
18	Sasaki H, Shimizu S, Okuda K, et al: Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. Lung Cancer. 64:295–300. 2009. View Article : Google Scholar : PubMed/NCBI
19	Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 97:643–655. 2005. View Article : Google Scholar : PubMed/NCBI
20	Sasaki H, Endo K, Takada M, et al: EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer. 58:324–328. 2007. View Article : Google Scholar : PubMed/NCBI
21	Nie Q, Wang Z, Zhang GC, et al: The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib. Eur J Pharmacol. 570:175–181. 2007. View Article : Google Scholar
22	Liu W, He L, Ramírez J, et al: Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res. 71:2423–2427. 2011. View Article : Google Scholar : PubMed/NCBI
23	Suzuki M, Kageyama S, Shinmura K, et al: Inverse relationship between the length of the EGFR CA repeat polymorphism in lung carcinoma and protein expression of EGFR in the carcinoma. J Surg Oncol. 98:457–461. 2008. View Article : Google Scholar : PubMed/NCBI
24	Ichihara S, Toyooka S, Fujiwara Y, et al: The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer. 120:1239–1247. 2007. View Article : Google Scholar : PubMed/NCBI
25	Nomura M, Shigematsu H, Li L, et al: Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLos One. 4:715–727. 2007.PubMed/NCBI
26	Sasaki H, Okuda K, Takada M, et al: A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer. J Cancer Res Clin Oncol. 134:1371–1376. 2008. View Article : Google Scholar : PubMed/NCBI
27	Girard N, Lou E, Azzoli CG, et al: Analysis of genetic variants in never-smokers with lung cancer facilitated by an internet-based blood collection protocol: a preliminary report. Clin Cancer Res. 16:755–763. 2010. View Article : Google Scholar : PubMed/NCBI